| 18F-Fdg-Pet/Ct | 37 |
| Accessory breast tissue | 1 |
| Adalimumab | 94 |
| Adverse event | 155 |
| Aggressive | 381 |
| Angiolipoma | 371 |
| Angiosarcoma | 190 |
| Anthracyclines | 299 |
| Arab culture | 329 |
| Arfi elastography | 134 |
| Artificial intelligence | 203 |
| Axilla | 163, 195 |
| Axillary dissection | 163, 289 |
| Axillary lymph node metastases | 37, 203 |
| Axillary reverse lymphatic mapping | 1 |
| Axillary ultrasound | 37 |
| Barriers | 329 |
| Benign | 248 |
| Bioempedance spectroscopy | 148 |
| Biomarkers | 235 |
| Body mass index | 271 |
| Bone metastasis | 286 |
| BRCA mutations | 323 |
| Breast | 30, 172, 190, 279, 343, 360, 371 |
| Breast calcification | 13 |
| Breast cancer | 1, 6, 63, 74, 79, 85, 91, 105, 134, 141, 148, 155, 167, 182, 199, 222, 229, 235, 252, 258, 292, 306, 315, 375 |
| Breast cancer risk | 108 |
| Breast cancer screening | 79 |
| Breast cancer screening behaviors | 329 |
| Breast cancer surgery | 55 |
| Breast carcinoma | 271, 289 |
| Breast carcinomas | 336 |
| Breast conserving therapy | 127 |
| Breast disease | 248 |
| Breast imaging | 286 |
| Breast implant | 381 |
| Breast lesions | 48 |
| Breast mass | 381 |
| Breast reconstruction | 105 |
| Breast ultrasonography | 163, 199 |
| Breast-conserving surgery | 315 |
| Breast-conserving therapy | 55 |
| Breast-Q | 127 |
| Cancer | 172, 203 |
| Cardiotoxic agents | 299 |
| Care pathway | 222 |
| Case report | 94 |
| Cd3D | 141 |
| Chemotherapy | 289, 299 |
| Chest scan | 91 |
| Cholesterol | 108 |
| Circumferential volume measurement | 148 |
| Citation | 258 |
| Clinical features | 360 |
| Clinical practices | 205 |
| Colonic metastasis | 375 |
| Contralateral prophylactic mastectomy | 16 |
| COVID-19 | 306 |
| Covid-19 | 74, 85, 91, 289 |
| Cystic neutrophilic granulomatous mastitis | 94 |
| De novo breast cancer | 85 |
| De-escalation | 6 |
| Desmoid | 381 |
| Diagnostic performance | 37 |
| Dietary fat intake | 108 |
| Direct-to-implant reconstruction | 55 |
| Ductal carcinoma in situ | 205, 336 |
| Ductography | 279 |
| ECG | 299 |
| Elastin fiber | 134 |
| Estrogen receptor | 167 |
| Extra-mammary | 252 |
| Fat grafting | 105 |
| Fibroadenoma | 134 |
| Fibromatosis | 381 |
| Foxo1 | 141 |
| Galactocele | 102 |
| Gastric metastasis | 375 |
| Gastrointestinal tract metastasis | 375 |
| Gata3 expression | 229 |
| Genetic counseling | 16 |
| Germline brca mutation | 16 |
| Granulomatous mastitis | 195 |
| Gynecomastia | 371 |
| Hemangioma | 190 |
| HER2 | 315 |
| Her2 | 63 |
| Hereditary breast cancer | 16 |
| Histopathological findings | 360 |
| Histopathology | 229 |
| Hormonal therapy | 155, 292 |
| Hyperprolactinemia | 102 |
| Idiopathic granulomatous mastitis | 94 |
| Il-2 | 141 |
| Il-2Ra | 141 |
| Immediate breast reconstruction | 55 |
| Immunohistochemistry | 21, 229 |
| Implant-based reconstruction | 55 |
| In silico analysis | 235 |
| In situ | 343 |
| Indeterminate lesion | 252 |
| Innovative approaches | 205 |
| Intraductal | 371 |
| Intraductal carcinoma | 343 |
| Intraductal proliferations | 279 |
| Invasive ductal carcinoma | 271 |
| Invasive lobular carcinoma | 375 |
| Invasive papillary carcinoma | 360 |
| Kidney injury molecule-1 | 336 |
| Lupus erythematosus | 13 |
| Lupus mastitis | 13 |
| Lymphedema | 148 |
| Machine learning | 203 |
| Magnetic resonance imaging | 172, 199 |
| Male | 371 |
| Male breast cancer | 199, 323 |
| Malignant | 343 |
| Mammography | 172, 199 |
| Mastalgia | 248 |
| Metastasis | 252, 286 |
| Metastatic cancer | 85 |
| Mir-490 | 141 |
| Molecular subtype | 353 |
| Molecular subtypes of breast carcinoma | 271 |
| Mono-unsaturated fatty acid | 108 |
| Mri | 37, 79, 190 |
| Mucinous | 30 |
| Mucinous carcinoma | 353 |
| Mucormycosis | 289 |
| Muslim Arab Iraqi women | 329 |
| Neo-adjuvant therapy | 6 |
| Neoadjuvant chemotherapy | 167, 271, 289 |
| Neoadjuvant systemic therapy | 306 |
| Neuroendocrine | 30 |
| Neutrophil gelatinase-associated lipocalin | 336 |
| New version | 48 |
| Nfat5 | 141 |
| Nipple eczema | 102 |
| Oncology department | 74 |
| Oncoplastic reconstruction | 127 |
| Pandemic | 85 |
| Panniculitis | 13 |
| Papilloma | 371 |
| Pathological complete response | 271 |
| Pathology features | 323 |
| Patient reported outcome | 155 |
| Patient satisfaction | 63, 127 |
| Patient-related delay time | 85 |
| Personal health records | 155 |
| Phldb | 235 |
| Phyllodes tumors | 343 |
| Positive lymph nodes | 163 |
| Precision medicine | 205 |
| Prediction | 203 |
| Pregnancy | 195 |
| Progesterone receptor | 167 |
| Prognosis | 323, 336, 353 |
| Programmed cell death protein 1 (Pd-1) | 21 |
| Programmed death-ligand 1 (Pd-L1) | 21 |
| Quality of life | 155, 292 |
| Quality-of-life | 148 |
| Radical lumpectomy | 127 |
| Radiomics | 203 |
| Receptor change | 167 |
| Recurrence | 315 |
| Research | 258 |
| Risk factors | 79, 182 |
| Risk-reducing salpingo-oophorectomy | 16 |
| Sars-Cov-2 | 74, 91 |
| Saturated fatty acid | 108 |
| Screening | 16, 91, 182 |
| Sentinel lymph node biopsy | 37 |
| Sentinel node biopsy | 163 |
| Solid papillary | 30 |
| Staff viewpoint | 222 |
| Stereotactic core-needle biopsy | 279 |
| Subcutaneous | 63 |
| Success factors | 222 |
| Superb microvascular imaging | 48 |
| Surgery | 195, 306 |
| Survey | 205 |
| Survival | 182 |
| Synchronous neoplasms | 199 |
| Tertiary hospital | 74 |
| Trastuzumab | 63 |
| Treatment de-escalation | 205 |
| Triple-negative breast cancer | 21, 315 |
| Troponin I | 299 |
| Tumor necrosis factor alpha inhibitor | 94 |
| Turkish | 148 |
| Two-stage implantbased reconstructions | 55 |
| Ultrasonography | 48 |
| Ultrasound | 172 |
| Vus mutation | 16 |
| Women | 292 |
| Women’s health | 48 |